Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus

Inclusion Criteria: * Men and women between the ages of 18 and 65 years old, inclusive, at the time of screening; * Females of non-child bearing potential must be ≥1 year post-menopausal (confirmed by a serum follicle-stimulating hormone (FSH) levels ≥ 40 IU/mL) or documented as being surgically sterile, and females of child bearing potential must use two medically acceptable methods of contraception; * Male subjects must be willing to use clinically acceptable contraception during treatment and for 2 months after the last administration of REMD-477; * Normal or clinically-acceptable physical examination, laboratory test values, and 12-lead ECG (reporting heart rate and PR, QRS, QT, and QTcF) at screening; * Body mass index between 23 and 40 kg/m2, inclusive, at screening; * Diagnosed with Type 2 diabetes as defined by the current American Diabetes Association (ADA) criteria; * Subjects in Parts A and B only: Treatment-naive, controlled with diet and exercise, or treated with oral antidiabetic medications and willing to wash-out and discontinue oral medications during the study; * Fasting plasma glucose 126 - 270 mg/dL (7-15 mM), inclusive, at screening and at re-test on Day -1; * Subjects in Parts A and B only: Screening HbA1c of 7.0-10 % inclusive for subjects not currently taking any oral antidiabetic medications, or 6.5-9.5% for subjects receiving acceptable oral antidiabetic medications; * Subjects in Part C only: Screening HbA1c of 7.5-10 % inclusive for subjects on stable doses of metformin. Exclusion Criteria: * History of drug or alcohol abuse within the last 6 months or a positive illegal drug urine test result; * History or family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia; * History or family history of pheochromocytoma; * Known or suspected susceptibility to infectious disease (eg, taking immunosuppressive agents or has a documented inherited or acquired immunodeficiency); * Positive for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HbsAg), or hepatitis C antibodies (HepC Ab); * Participation in an investigational drug or device trial within 30 days of screening or within 5 times the half-life of the investigational agent in the other clinical study, if known, whichever period is longer; * Blood donor, or blood loss\>300 mL, within 30 days of Day 1; * Recent use (6 weeks prior to Screening) of thiazolidinediones, \>half-maximal dose sulfonylurea agent therapy, or any injectable antidiabetic agents (exenatide and other injectable GLP-1 agonists, insulin and insulin analogs, etc.); * Other gastrointestinal, cardiac, renal and CNS (i.e. hypoglycemia unawareness) conditions specific to diabetes that would pose additional risk to subject's safety or interfere with the study evaluation, procedures or completion; * Lipid panel profiles of non-HDL-C (total cholesterol minus HDL-C) \>219 mg/dL, LDL-C \>189 mg/dL, and/or fasting triglycerides \>499 mg/dL; * Female subject is pregnant or breastfeeding. Other inclusion and exclusion criteria may apply.